Abstract
The last 20 years have witnessed dramatic reductions in cardiovascular risk using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (“statins”) to lower levels of low-density lipoprotein cholesterol (LDL-C). Using this approach one...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have